Search:
This item requires a subscription.
Why you need to know about cyclic citrullinated peptide RDIP, Volume 6, Number 2.
Rheumatoid arthritis (RA) is a chronic, progressive multisystem autoimmune disease leading to significant morbidity and premature mortality. The recent focus in the management of RA has been to treat early and intensively to reduce the burden of disease. Anti-cyclic citrullinated peptide (anti-CCP) antibodies have helped greatly in this endeavour and have also given us insights into the pathophysiology of the condition. This article will highlight the importance of knowing about these pivotal antibodies.
To view this item, select one of the options below:
Purchase access
Sign in
email address
Password
Important
All the articles are in PDF format.
To view the articles you will need Adobe Acrobat Reader.
To download a copy, free of charge, please click here.